NextCure (NASDAQ:NXTC) Shares Down 1.1% – Time to Sell?

NextCure, Inc. (NASDAQ:NXTC) was down 1.1% during trading on Monday . The company traded as low as $0.37 and last traded at $0.39. Approximately 50,769 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 91,598 shares. The stock had previously closed at $0.39.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of NextCure in a research report on Monday, March 17th.

NextCure Trading Down 1.1 %

The business has a 50-day simple moving average of $0.67 and a 200 day simple moving average of $0.98. The stock has a market cap of $10.81 million, a P/E ratio of -0.18 and a beta of 0.89.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.07). As a group, equities analysts expect that NextCure, Inc. will post -1.87 earnings per share for the current year.

Hedge Funds Weigh In On NextCure

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tang Capital Management LLC boosted its holdings in NextCure by 7.3% in the 4th quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock valued at $540,000 after purchasing an additional 47,614 shares during the period. Renaissance Technologies LLC boosted its stake in NextCure by 27.9% in the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock worth $400,000 after buying an additional 113,300 shares in the last quarter. Peapod Lane Capital LLC bought a new position in shares of NextCure during the 4th quarter valued at $311,000. Geode Capital Management LLC increased its holdings in shares of NextCure by 14.2% in the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock worth $307,000 after buying an additional 27,812 shares during the period. Finally, Citadel Advisors LLC increased its stake in NextCure by 40.6% in the 4th quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after purchasing an additional 22,724 shares during the period. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.